Commerce Bank lifted its stake in Thermo Fisher Scientific Inc (NYSE:TMO) by 2.3% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 224,186 shares of the medical research company’s stock after acquiring an additional 5,107 shares during the period. Commerce Bank owned 0.06% of Thermo Fisher Scientific worth $42,416,000 at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of TMO. Vanguard Group Inc. increased its position in Thermo Fisher Scientific by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 26,600,394 shares of the medical research company’s stock worth $4,640,970,000 after buying an additional 629,093 shares during the period. BlackRock Inc. increased its position in Thermo Fisher Scientific by 1.6% in the 2nd quarter. BlackRock Inc. now owns 23,355,469 shares of the medical research company’s stock worth $4,074,828,000 after buying an additional 366,584 shares during the period. Capital Research Global Investors increased its position in Thermo Fisher Scientific by 29.8% in the 2nd quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock worth $3,019,185,000 after buying an additional 3,973,136 shares during the period. State Street Corp increased its position in Thermo Fisher Scientific by 1.0% in the 1st quarter. State Street Corp now owns 16,085,954 shares of the medical research company’s stock worth $2,470,802,000 after buying an additional 164,367 shares during the period. Finally, Capital World Investors increased its position in Thermo Fisher Scientific by 6.1% in the 2nd quarter. Capital World Investors now owns 11,759,734 shares of the medical research company’s stock worth $2,051,721,000 after buying an additional 671,637 shares during the period. 86.16% of the stock is currently owned by institutional investors and hedge funds.
Shares of Thermo Fisher Scientific Inc (NYSE:TMO) traded up $1.42 during trading hours on Thursday, hitting $183.87. The stock had a trading volume of 2,262,900 shares, compared to its average volume of 1,561,349. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81. The firm has a market cap of $73,161.61, a price-to-earnings ratio of 20.05, a PEG ratio of 1.67 and a beta of 1.06. Thermo Fisher Scientific Inc has a one year low of $139.88 and a one year high of $201.20.
Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.24 by $0.07. The business had revenue of $5.12 billion for the quarter, compared to analyst estimates of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. Thermo Fisher Scientific’s quarterly revenue was up 13.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.03 EPS. equities research analysts anticipate that Thermo Fisher Scientific Inc will post 9.36 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be paid a $0.15 dividend. This represents a $0.60 annualized dividend and a yield of 0.33%. The ex-dividend date of this dividend is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio is 10.19%.
TMO has been the topic of several recent analyst reports. Cowen reaffirmed an “outperform” rating and issued a $220.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Sunday, September 10th. Leerink Swann lifted their price objective on Thermo Fisher Scientific from $190.00 to $207.00 and gave the stock an “outperform” rating in a report on Monday, October 9th. Deutsche Bank set a $226.00 price objective on Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Thursday, October 26th. Zacks Investment Research lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Finally, Goldman Sachs Group began coverage on Thermo Fisher Scientific in a report on Tuesday, September 26th. They set a “buy” rating and a $225.00 price objective on the stock. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $205.21.
In related news, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total value of $9,419,500.00. Following the sale, the chief executive officer now owns 252,577 shares of the company’s stock, valued at approximately $47,582,981.03. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.49% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: This story was first published by Stock Observer and is owned by of Stock Observer. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.thestockobserver.com/2017/12/07/thermo-fisher-scientific-inc-tmo-position-lifted-by-commerce-bank.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.